Immunoparesis recovery 1 year after ASCT is independently associated with favorable survival in patients with symptomatic multiple myeloma who undergo autologous stem cell transplantation
Autor: | Ying Tian, Yanchen Li, Zhipeng Wu, Jie Li, Wenming Chen, Yun Leng, Aijun Liu, Guangzhong Yang, Huijuan Wang, Guorong Wang, Wen Gao, Zhangyong Ren, Yin Wu |
---|---|
Rok vydání: | 2017 |
Předmět: |
Oncology
Adult Male medicine.medical_specialty Disease-Free Survival 03 medical and health sciences 0302 clinical medicine Autologous stem-cell transplantation Internal medicine medicine Humans In patient Autografts Multiple myeloma Aged Hematology business.industry Medical record Incidence (epidemiology) Hematopoietic Stem Cell Transplantation General Medicine Middle Aged medicine.disease Survival Rate Regimen Immune System Diseases 030220 oncology & carcinogenesis Conventional chemotherapy Female business Multiple Myeloma 030215 immunology Follow-Up Studies |
Zdroj: | Annals of hematology. 98(5) |
ISSN: | 1432-0584 |
Popis: | Immunoparesis is defined as a reduction in the levels of one, two, or three uninvolved immunoglobulins. However, there are very limited data on the incidence and prognostic significance of immunoparesis recovery 1 year after autologous stem cell transplantation (ASCT) in MM. We reviewed medical records of de novo MM patients who received ASCT at Beijing Chao Yang hospital. One hundred eight MM patients were included in the study. Conventional chemotherapy was administered as induction regimen in 16 patients (14.8%), whereas novel agents were used in 92 patients (85.2%). Most patients had immunoparesis at diagnosis (89.1%) and at the moment of ASCT as well (75%). After a median follow-up of 49 months, in the group with immunoglobulin recovery 1 year after ASCT, there was a trend towards longer progression-free survival (PFS) than in the group with immunoparesis (P = 0.054). And overall survival (OS) was significantly longer in patients with immunoparesis recovery (P = 0.004). In multivariate analysis, immunoparesis recovery 1 year after ASCT was independently associated with improved OS (P = 0.016). In conclusion, lack of immunoparesis recovery 1 year after ASCT in MM patients is associated with significantly shorter OS and this group of patients needs new treatment strategy to improve the prognosis. |
Databáze: | OpenAIRE |
Externí odkaz: |